Gossamer Bio (Gossamer Bio) Price-to-Tangible-Book : 2.66 (As of May. 05, 2024)

View and export this data going back to 2019. Start your Free Trial

What is Gossamer Bio Price-to-Tangible-Book?

As of today (2024-05-05), Gossamer Bio's share price is $0.74. Gossamer Bio's Tangible Book per Share of Dec. 2023 for the quarter that ended in Dec. 2023 was $0.28. Hence, Gossamer Bio's Price to Tangible Book Ratio of today is 2.66.

The historical rank and industry rank for Gossamer Bio's Price-to-Tangible-Book or its related term are showing as below:

GOSS' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.23 Med: 3.28 Max: 16.95
Current: 2.66

During the past 8 years, Gossamer Bio's highest Price to Tangible Book Ratio was 16.95. The lowest was 2.23. And the median was 3.28.

GOSS's Price-to-Tangible-Book is ranked better than
51.64% of 1222 companies
in the Biotechnology industry
Industry Median: 2.715 vs GOSS: 2.66

A closely related ratio is called PB Ratio. As of today, Gossamer Bio's share price is $0.74. Gossamer Bio's Book Value per Sharefor the quarter that ended in Dec. 2023 was $0.28. Hence, Gossamer Bio's P/B Ratio of today is 2.66.

Gossamer Bio Price-to-Tangible-Book Historical Data

The historical data trend for Gossamer Bio's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gossamer Bio Price-to-Tangible-Book Chart

Gossamer Bio Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Price-to-Tangible-Book

Get a 7-Day Free Trial

2.73

2.23

7.06

16.95

3.28

Gossamer Bio Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Price-to-Tangible-Book	Get a 7-Day Free Trial															16.95	-	-	1.79	3.28

Competitive Comparison of Gossamer Bio's Price-to-Tangible-Book

For the Biotechnology subindustry, Gossamer Bio's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Gossamer Bio's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Gossamer Bio's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Gossamer Bio's Price-to-Tangible-Book falls into.

Gossamer Bio Price-to-Tangible-Book Calculation

Gossamer Bio's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book	=	Share Price	/	Tangible Book per Share (Q: Dec. 2023 )
	=	0.74	/	0.278
	=	2.66

It can also be calculated from the numbers for the whole company:

Price to Tangible Book	=	Market Cap	/	Tangible Equity
	=	Market Cap	/	(Total Stockholders Equity	-	Preferred Stock	-	Intangible Assets)

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.

Gossamer Bio Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Gossamer Bio's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.

Gossamer Bio (Gossamer Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gossamer Bio Inc (NAS:GOSS) » Definitions » Price-to-Tangible-Book

Comparable Companies

Traded in Other Exchanges

4GB:Germany

Address

3013 Science Park Road, Suite 200, San Diego, CA, USA, 92121

Website

https://www.gossamerbio.com

Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.

Executives

Sandra Milligan	director	2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Bryan Giraudo	officer: Chief Financial Officer	7707 GATEWAY BOULEVARD, SUITE 140, NEWARK CA 94560
Richard Aranda	officer: Chief Medical Officer	3013 SCIENCE PARK ROAD, SAN DIEGO CA 92121
Faheem Hasnain	director, officer: Executive Chairman	14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142
Waage Christian	officer: EVP & General Counsel	RECEPTOS, INC., 10835 ROAD TO THE CURE, SUITE 205, SAN DIEGO CA 92121
Caryn Peterson	officer: EVP, Regulatory Affairs	3013 SCIENCE PARK ROAD, SAN DIEGO CA 92121
Laura Carter	officer: Chief Scientific Officer	3013 SCIENCE PARK ROAD, SAN DIEGO CA 92121
Luisa Salter-cid	officer: Chief Scientific Officer	C/O GOSSAMER BIO, INC., 3013 SCIENCE PARK ROAD, SUITE 200, SAN DIEGO CA 92121
Jakob Dupont	officer: Chief Medical Officer	C/O ONCOMED PHARMACEUTICALS, INC., 800 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Sheila Gujrathi	director, officer: President & CEO	10835 ROAD TO THE CURE, SUITE 205, SAN DIEGO CA 92121
Omega Fund V Gp, L.p.	10 percent owner	888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199
Omega Fund V Gp Manager, Ltd.	10 percent owner	888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199
Omega Fund V, L.p.	10 percent owner	888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199
Otello Stampacchia	director, 10 percent owner	888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199
Russell J. Cox	director	C/O JAZZ PHARMACEUTICALS, PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2